Posting FDA new drug application reviews [9]

JAMA

Volumn 298, Issue 8, 2007, Pages 863-864

  Turner, Erick H ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG APPROVAL; DRUG PACKAGING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; LETTER; PRIORITY JOURNAL; UNITED STATES; DRUG SURVEILLANCE PROGRAM; INFORMATION DISSEMINATION; NOTE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG APPROVAL; INFORMATION DISSEMINATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34548071931     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.8.863     Document Type: Letter

References (6)

1. Psaty BM, Charo RA. FDA responds to Institute of Medicine drug safety recommendations - in part. JAMA. 2007;297(17):1917-1920.
2. Turner EH. A taxpayer-funded clinical trials registry and results database. PLoS Med. 2004;1(3):e60.
3. The future of drug safety: promoting and protecting the health of the public: FDA's response to the Institute of Medicine's 2006 report. US Food and Drug Administration Web site. http://www.fda.gov/oc/reports/iom013007.html. Accessed July 13, 2007.
4. Drugs@FDA, FDA Approved Drug Products. US Food and Drug Administration, Center for Drug Evaluation and Research Web site. http://www.accessdata.fda.gov/ scripts/cder/drugsatfda. Accessed July 13, 2007.
5. Jüni P, Reichenbach S, Egger M. COX 2 inhibitors, traditional NSAIDs, and the heart. BMJ. 2005;330(7504):1342-1343.
6. Committee on Government Reform, House of Representatives, 109th Congress, 1st Session. A Citizen's Guide on Using the Freedom of Information Act and the Privacy Act of 1974 to Request Government Records [Report 109-226]. Washington, DC: US Government Printing Office;2005.